EnGeneIC

What EnGeneIC does

EnGeneIC Limited is a clinical-stage biopharmaceutical company founded in 2001, incorporated in Bermuda, headquartered in Sydney, Australia, with a US subsidiary (EnGeneIC Inc) in New York. The company develops targeted cyto-immunotherapy for solid tumors using its proprietary EnGeneIC Dream Vector (EDV) nanocell platform — bacterially-derived 400nm nanocells that can carry up to approximately one million drug molecules, functional nucleic acids (siRNA, miRNA, plasmid DNA), or immune-stimulating adjuvants directly into tumor cells while bypassing normal tissue and the blood-brain barrier. The platform combines direct cytotoxic payload delivery with simultaneous activation of both innate and adaptive anti-tumor immune responses (macrophages, NK cells, dendritic cells, and CD8+ T-cells), and is modular across cancer types by changing the targeting antibody — including CD-19 for B-cell lymphoma, asialoglycoprotein for liver cancer, and anti-ganglioside G2 for melanoma and neuroblastoma.

The company's lead clinical programs target glioblastoma multiforme, pancreatic cancer, mesothelioma, and other EGFR-expressing solid tumors. EnGeneIC holds 435+ granted patents across 19 patent families, has received FDA Orphan Drug Designation for glioblastoma (March 2017) and FDA Fast-Track Designation for pancreatic cancer (December 2023), and has reported a 37.5% response rate across 133 patients in first-in-man safety studies, with a 41-week median survival in mesothelioma patients. Manufacturing is conducted at an in-house pilot facility and through CDMO partner BioCina, with a research collaboration with Takeda for EDV-based immunomodulatory therapies and a clinical partnership with the Asbestos Diseases Research Institute for the MesomiR-1 mesothelioma program.

As a pre-revenue clinical-stage company, EnGeneIC's business model centers on advancing investigational therapies through clinical trials toward regulatory approval, with future revenue expected from licensing deals, milestone payments, and ultimately product commercialization. The company currently operates with 11-50 employees, has raised approximately $14.1 million in disclosed funding across multiple rounds since 2011 (including a $10M Series B in January 2015 led by a US institutional investor, with co-investors Foley Ventures and Shepherd Kaplan Krochuk), and runs clinical trials in Australia with planned expansion to Singapore and the United States for a Phase IIa glioblastoma program. Leadership comprises Joint CEO and Founder Jennifer MacDiarmid, Co-Founder and Co-Managing Director Himanshu Brahmbhatt, COO David Seaton, and CFO William Harris, with independent directors Professor Bryan Williams and Dr. Mark Levitt.

Name

EnGeneIC

Legal name

EnGeneIC Limited

Website

https://engeneic.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

11–50 employees

Short description

EnGeneIC is a clinical-stage biopharmaceutical company developing targeted cancer therapies via its proprietary EDV nanocell platform, which delivers chemotherapeutics and nucleic acids directly to tumors while stimulating anti-tumor immune responses. It serves patients with aggressive solid tumors, notably glioblastoma and pancreatic cancer.

Ownership category

akta.pro rank

Product category

Oncology Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

akta.pro secondary industries

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG)

Keywords

• Targeted cancer therapy
• Nanocell drug delivery
• Cyto-immunotherapy platform
• Oncology drug development
• Brain tumor therapy

Headquarters

HQ city

Sydney

HQ country

Australia

HQ region

Oceania

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure

Revenue model

1. Clinical-stage biopharmaceutical development: EnGeneIC is a clinical-stage biopharmaceutical company developing novel cancer therapies based on its proprietary EDV nanocell platform. Revenue is derived from development milestones, licensing deals, and ultimately product commercialization as the company advances multiple clinical-stage programs through regulatory approval.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

EnGeneIC researches, develops, and manufactures investigational targeted cancer therapies built on its proprietary EDV (EnGeneIC Dream Vector) nanocell platform — bacterially-derived 400nm nanocells that deliver chemotherapeutics and functional nucleic acids (siRNA/miRNA) directly to tumor cells while simultaneously stimulating anti-tumor immune responses. The pipeline includes EGFR-targeted EDV therapies for glioblastoma multiforme, doxorubicin-loaded EDVs, microRNA replacement therapies (e.g., miR-16a for mesothelioma), and a COVID-19 EDV vaccine, all delivered through clinical-stage trials at partnered hospitals.

Product overview

EnGeneIC is a clinical-stage biopharmaceutical company developing its proprietary EDV™ (EnGeneIC Dream Vector) nanocell platform, a first-in-class cyto-immunotherapy technology. The platform comprises targeted nanocells (400nm) derived from bacteria that deliver therapeutic payloads directly to tumors while activating anti-tumor immune responses. The core EDV platform supports multiple therapeutic applications including EGFR-targeted therapies for glioblastoma and other solid tumors, microRNA replacement therapies, and a COVID-19 EDV vaccine. The platform is designed to carry various payloads including chemotherapeutic drugs (doxorubicin, PNU159682), functional nucleic acids (siRNA, miRNA, plasmid DNA), and immune-stimulating adjuvants.

Differentiator

Problem solved

Functional benefit

Products and services

• EnGeneIC Dream Vector (EDV™) Nanocell Platform First-in-class cyto-immunotherapy platform using antibody-targeted, non-living bacterially-derived nanocells (400nm) to deliver chemotherapeutics and functional nucleic acids directly into tumor cells, bypassing the blood-brain barrier and stimulating anti-tumor immune responses. The platform is versatile across cancer types — the targeting antibody can be changed (e.g., EGFR for solid tumors, CD-19 for B-cell lymphoma, asialo-glycoprotein for liver cancer, anti-ganglioside G2 for melanoma and neuroblastoma). Each nanocell carries up to ~1 million drug molecules and is lyophilizable for 2+ year shelf storage.
• EGFR-Targeted EDV Therapy Investigational targeted cyto-immunotherapy using EGFR-targeted EDV nanocells loaded with doxorubicin and an immune-modulating adjuvant, designed to treat patients with recurrent glioblastoma multiforme and other EGFR-expressing solid tumors. Demonstrated ability to bypass the blood-brain barrier and deliver therapeutic payloads directly to brain tumors.
• EDV Doxorubicin Bacterially-derived nanocell particles loaded with the chemotherapeutic doxorubicin and an immune-modulating adjuvant, designed to directly target cancer cells while simultaneously activating an anti-tumor immune response. Used as the cytotoxic payload within EGFR-targeted EDV therapy for glioblastoma and other EGFR-expressing solid tumors.
• COVID-EDV Vaccine World-first nanocellular anti-COVID-19 vaccine using EDV technology to deliver interferon-stimulating molecules together with COVID-19 spike protein, producing a therapeutic vaccine intended to be effective against all variants and designed for immune-compromised patients. Developed from the EDV nanocell platform and trialled in healthy volunteers.

Quantifiable outcome

• 37.5% response rate in first-in-man safety studies with 50/133 patients showing clinical benefit
• +3 more outcomes

Named customers2 records

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core and minor.

• BioCinacoreStrategic or Co-development PartnerEnGeneIC selected BioCina as global CDMO (Contract Development and Manufacturing Organization) to advance their groundbreaking cancer treatment. BioCina will support manufacturing scale-up for EDV-based cancer therapeutics.
• TakedacoreStrategic or Co-development PartnerResearch collaboration with Takeda to develop EDV-based immunomodulatory therapies for oncology. Collaboration announced October 2016.
• Asbestos Diseases Research InstitutecoreStrategic or Co-development PartnerCollaboration for MesomiR-1 Phase 1 trial in late stage mesothelioma patients. Joint initiative to advance microRNA-based treatment using EDV nanocells.
• Foundation for Sarcoidosis ResearchminorStrategic or Co-development PartnerEnGeneIC provided support for Foundation for Sarcoidosis Research's first New York fundraiser.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Nanobiotix: French clinical-stage nanomedicine company developing nanoparticle-based cancer therapeutics (Hafnium oxide nanoparticles, NBTXR3). Directly comparable to EnGeneIC as a nanoparticle-delivery oncology platform targeting solid tumors with externally validated IP and clinical data.
• Codiak BioSciences: Developed exosome-based therapeutic delivery platforms (engEx) for cancer and other diseases. Comparable to EnGeneIC's EDV nanocell platform as a biologic nanocarrier enabling targeted payload delivery to specific cell types.
• Bind Therapeutics: Acquired by Pfizer in 2016, Bind developed Accurins — targeted nanoparticle therapeutics for oncology. Highly comparable as a nanoparticle-platform company using targeted delivery to solid tumors with platform optionality across indications.
• Cerulean Pharma: Developed tumor-targeted nanoparticle-drug conjugates (CRLX101, CRLX301) using a cyclodextrin-PEG-based nanoparticle platform. Closely aligned with EDV nanocells as a tumor-targeted nanocarrier for oncology payloads.
• CytImmune Sciences: Developed tumor-targeted gold nanoparticle delivery platform (Aurimune) loaded with TNF-alpha. Closely parallel to EnGeneIC's antibody-targeted nanocell approach for delivering potent oncology payloads with reduced systemic toxicity.

Regional players

• Telix Pharmaceuticals: Australian-headquartered clinical-stage oncology biotech developing targeted radiopharmaceuticals. Comparable as a regionally-similar Australian oncology platform with multiple clinical programs and a similar commercialization pathway to US/European markets.

Emerging players

• Immatics: Clinical-stage biotech developing TCR-based immunotherapies for solid tumors. Comparable as an emerging-platform oncology company developing targeted cancer therapies with multiple clinical-stage programs in solid tumor indications.
• Kintara Therapeutics: Clinical-stage oncology company developing therapeutics for glioblastoma multiforme (VAL-083). Comparable as a small-cap clinical-stage peer sharing EnGeneIC's high-risk, high-unmet-need GBM focus with similar Phase II/III trajectory requirements.
• Adaptimmune Therapeutics: Clinical-stage cell therapy company developing engineered TCR therapies for solid tumors. Comparable as a clinical-stage oncology platform peer pursuing novel modalities against hard-to-treat solid tumor indications with platform optionality.

Broad incumbents

• Merrimack Pharmaceuticals: Developed liposomal cancer therapeutics (Onivyde) using nanoliposomal delivery. Comparable as a broader oncology platform player using encapsulated delivery vehicles for cytotoxic payloads in solid tumor indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@engeneic
• Xx.com/engeneic
• LinkedInlinkedin.com/company/engeneic-ltd

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EnGeneIC